Henry Ford Hospital Medical Journal
Volume 39
Number 1 Festschrift: In Honor of Raymond C.
Mellinger

Article 7

3-1991

A Thyroid Testing Algorithm: Results of a Pilot Study
Hossam Ibrahim
Malachi J. McKenna
Carolyn S. Feldkamp

Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal
Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons

Recommended Citation
Ibrahim, Hossam; McKenna, Malachi J.; and Feldkamp, Carolyn S. (1991) "A Thyroid Testing Algorithm:
Results of a Pilot Study," Henry Ford Hospital Medical Journal : Vol. 39 : No. 1 , 30-34.
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol39/iss1/7

This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has
been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health
System Scholarly Commons.

A Thyroid Testing Algorithm: Results of a Pilot Study

Hossam Ibrahim, MD,* Malachi J. McKenna, MD,^ and Carolyn S. Feldkamp, PhD^
We conducted a pUot study to evaluate an algorithm for thyroid function testing consisting of initial
serum thyrotropin values, measured by a sensitive immunoradiometric assay (TSH-IRMA). foUowed
by a computer-directed decision to order further studies. We divided 216 outpatients according to
their serum TSH-IRMA values as follows: suppressed (< 0.1 mUlL. group I); low (0.1 to 0.4 mUlL.
group H); normal (0.5 to 5.0 mUlL. group 111); and high (> 5.0 mU/L. group IV). Thyroxine (TJ, resin
uptake (RU). andfree thyroxine index (FTI) tests on groups I.ll. and IV revealed that T^andRU were
normal for most patients in all groups and FTI was normal in 80% of group 1.93.4 % of group ll. and
93.3% of group IV. All patients in group I were designated hyperthyroid from either an exogenous or
endogenous source. All patients in group ll were clinically euthyroid except one; 50% were taking
either L-thyroxine or propylthiouracil and 50% had no identifiable thyroid di.sease. Patients in group
IV were hypothyroid. OveraU. TSH was more effective in detecting hoth hypothyroidism and
hyperthyroidism than either serum T^, RU ratio, or hoth combined in FTI since resuUs of these
measures fell in the normal range for most patients in all groups. We conclude that a computerdirected algorithm with TSH-IRMA as the initial step is useful in the evaluation of suspected thyroid
dysfunction, that T^ and RU may be helpful when TSH is abnormal or borderline, and lhal suppressed
TSH-IRMA values (<0.1 mUlL) hut not low values (0.1 to 0.4 mU/L) are consistently associated with
hyperthyroidism. Results obtained by use of the algorithm may he misleading in patients with
hypothalamic pituitary dysfunction, hut its use should reduce the numher of redundant and
unnecessaiy T^ and RU tests. (Henry Ford Hosp Med J 1991 ;39:30-4)

T

he use of thyroid-stimulating hormone-immunoradiometric assay (TSH-IRMA) has improved the sensitivity and
specificity of the TSH assay (1-3). Specificity is enhanced by
use of monoclonal antibodies (4). The least detectable dose of
TSH-IRMA, unlike that of conventional radioimmunoassay, is
well below the lower limit of the normal range so that low values
can be distinguished from normal (5). Patients with hyperthyroidism have values below the detection limit in even the most
sensitive assays (6). This ability to distinguish euthyroid subjects from patients with hyperthyroidism has prompted the suggestion that TSH-IRMA can accurately predict normalcy and
uncover early enhanced or suppressed TSH secretion (7). Conditions with increased TSH secretion include the entire spectrum of primary thyroid gland failure as well as the rare instance
of pituitary hyperthyroidism. In contrast, suppressed TSH secretion could be secondary to a variety of conditions including
hyperthyroidism, autonomous thyroid nodule, thyroid hormone
therapy, use of medications such as dopamine or glucocorticoids, pregnancy, nonthyroidal illness, and pituitary hypothyroidism (8). Though the relationship of TSH and free thyroxine
(T4) is log-linear in ambulatory patients with normal pituitary
function, there is significant scatter at low TSH levels and no
correlation between these parameters in hospitalized patients
(9). Nonetheless, the diagnostic efficiency of TSH-IRMA is
better than that of either free or total T^ measurements (10).
With that in mind, we and others have recommended measurement of TSH-IRMA as the initial test of thyroid function in patients with suspected thyroid disea.se (6-12). We designed a di-
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agnostic algorithm, termed directed TSH (DRTSH), in which
TSH-IRMA values direct further evaluation by other thyroid
function tests (11).
The concept of DRTSH is that because a normal TSH-IRMA
level is consistent with normal thyroid function, except in relatively rare cases, no additional tests of thyroid function are required. On the other hand, low or high TSH-IRMA may reflect a
thyroid abnormality and additional tests are indicated to clarify
the clinical situation in terms of initial diagnosis or appropriate
therapy, DRTSH automatically orders T^, resin uptake (RU),
and free thyroxine index (FTI) tests.
Our TSH normal range is 0.4 to 5.0 mU/L with a detection
limit of 0.1 mU/L. The DRTSH limits set for follow-up testing
were based on these assumptions: 1) in the absence of pituitary
or hypothalamic disease or other factors affecting TSH secretion, low TSH values (< 0.5 mU/L) represent either hyperthyroidism when TSH is < 0.1 mU/L or a variety of other conditions
when TSH is < 0.1 to 0.4 mU/L; 2) normal values of TSH (0.5 to
5.0 mU/L) are likely to represent euthyroidism; 3) TSH values

Suhmilled for puhlicalion: May3l, 1990,
Accepled for publication: Septeniber 28, 1990,
•Fellow, 1988-1990, Division of Endocrinology and Metaboli,sm, Henry Ford Hospital.
Current address: Creve Coeur, MO,
tFormerly Division of Endocrinology and Metabolism, Henry Ford Ho,spilal, Currenlly
Department of Endocrinology and Diabetes, St, Vincent's Hospital, Dublin, Ireland,
tDepartment of Pathology, Ligand Assay Laboratory, Henry Ford Hospital,
Address correspondence to Dr, Feldkamp, Department of Pathology, Ligand Assay Laboratory, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, Ml 48202,

Thyroid Testing Algorithm—Ibrahim et al

Table 1
Clinical Data
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*Tj was 17,0, repeat TSH in 2 weeks was < 0,1,
tOne patient was receiving both estrogen and thyroxine,
$One patient was pregnant,
§AII had Graves' di,sease and were receiving propylthiouracil.
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Fig 1—Distribution (%) of concentrations of TSH-IRMA among
216 patients evaluated for thyroidal illness.

of 5.0 to 10.0 mU/L are likely to represent primary hypothyroidism; and 4) TSH values > 10.0 mU/L represent primary hypothyroidism in absence of rare secondary hyperthyroidism. It was
projected that this program would be efficient and cost-saving.
The complexities of interpreting borderline TSH-IRMA or apparent discrepancies are described in abundance (6-12).
The purpose of this report is to describe the function of the algorithm and to examine whether the T^, RU, and FTI tests directed by the algorithm were consistent with the patients' clinical conditions. Furthermore, we wished to establish whether the
T^, RU, and FTI follow-up tests directed by the algorithm were
useful, i.e., provided new information or confirmed the diagnosis suggested by TSH-IRMA.

Study Design
Our computer was programmed to order T^ and RU and to
calculate FTI if the TSH value was < 0.5 mU/L or > 5.0 to
10.0 mU/L. In addition, for the purpose of the study, T^, RU, and
FTI were measured on 30 consecutive patients with normal
TSH (0.5 to 5.0mU/L) andon 10 consecutive patients with high
TSH (> 10.0 mU/L). A total of 216 samples were tested for
TSH-IRMA over a six-week period, and the results were categorized into five groups according to TSH values.
We reviewed the medical records for all patients identified
by the algorithm with TSH value < 0.5 or > 5.0 mU/L to confirm
the presence or absence of primary hypothyroidism or primary
hyperthyroidism, to exclude the presence of pituitary and hy-
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pothalamic disorders, and to identify drugs or diseases known to
affect thyroid function tests, including L-thyroxine and antithyroid medications. Patients were considered I) hypothyroid if
TSH was > 5.0 mU/L, 2) hyperthyroid (endogenous or exogenous) if TSH was < 0.1 mU/L, or 3) euthyroid if TSH was 0.5 to
5.0 mU/L or if TSH was 0.1 to 0.4 mU/L in absence of drugs or
diseases known to interfere with thyroid function tests.

Assays
Serum TSH was determined by a sensitive immunoradiometric assay (TSH-IRMA) using Magic mab TSH kit (Ciba-Coming Diagnostic Corp., Medfield, MA) (normal range 0.4 to 5.0
mU/L), T4 by Gammacoat ('-^I) Total T^ Radioimmunoassay
kit (Baxter Health Care Corp., Dade Division, Cambridge, MA)
(normal range 5.0 to 11.0 pg/dL), and RU ratio by Magic T3 Uptake ('--^I) Radioassay kit (Ciba-Coming Diagnosfic Corp.)
(normal range 0.84 to 1.17). FTI was calculated as the product of
T4 and RU (normal range 4.5 to 11.0 )J.g/dL).

Results
Serum TSH
Fig 1 shows the distribufion of TSH-IRMA values in 216
consecutive samples: 20 (9.3%) had TSH-IRMA < 0.1 mU/L
(group I), 30 (13.9%) had TSH-IRMA 0.1 to 0.4 mU/L (group
II), 151 (69.9%) had TSH-IRMA 0.5 to 5.0 mU/L (group III), 6
(2.8%) had TSH-IRMA 5.0 to 10.0 mU/L, and 9 (4.2%) had
TSH-IRMA > 10.0 mU/L (group IV).
Table I shows a summary of the clinical data for groups 1, II,
and IV. The cases of hyperthyroidism are divided between primary hyperthyroidism and excessive replacement of thyroxine.
The medical records revealed that in many cases after TSHIRMA measurement the physician adjusted the thyroxine dose
in absence of noted clinical symptoms or signs of hyperthyroidism or hypothyroidism. In the nine hyperthyroid patients and in
the five hypothyroid patients, serum TSH-IRMA correctly predicted the diagnosis. All patients in group II except one were
euthyroid clinically. Group II was the most diverse group consisting of patients who were either normally euthyroid, euthyroid on propylthiouracil or thyroxine, euthyroid pregnant, or developing hyperthyroidism. Among all patients receiving thyroxine, approximately one-third were hypothyroid, one-third
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Table 2
Results of T4 and RU According to
Groups Based on TSH Results
Group 1
(n = 20)

RU
FTI

N
H
1,
N
H
1,
N
H
L

10 (.50% )
10(507f)
0 (0%)
16(80%)
2(10%)
2(10%)
16(80%)
4 (2O%0
0 (0%)

Group II
(n = iO)
2.1(76,6%)
5 (16,7%)
2(6,7%)
17(56,7%0
2 (6,7% )
11 (36,7%)
28 (93,4%)
1 (3,3%)
1 (3,3%)

30
20-

Group III
(n = 30)*

Group IV
(n= 15)

29 (96,7%)
1 (3,3%)
0 (0%)
26 (86,7%)
0 (0%)
4(13,3%)
30(100%)
0 (0%)
0(0%.)

14(93,3%)
0(0%)
1 (6,7%)
6(40%)
0 (0%)
9(60%)
14(93,3%)
0(0%)
1 (6,7%)

•Detailed informalion of Tj, RU, and FTI was oblained on only M} patients in group 111,
Tj = total thyroxine, RU = triiodothyronine resin uptake ratio, FTI = free thyroxine index,
N = normal, H = high, L = low.

were euthyroid, and one-third were hyperthyroid (10, 12, and 11
patients, respecfively).
Serum T^ and FTI
Of the 20 patients in group I. 10 (50%) had normal T^, 10
(50%) had high T^, and none had low T^ (Table 2). Ofthe 30 patients in group II, 23 (76.6%) had normal T^, 5 (16.7%) had high
T4, and 2 (6.7%) had low T^. Ofthe 30 subjects studied in group
111. all but one had normal serum T4. This subject with high serum T4 had low serum RU and normal FTI, consistent with
euthyroid status and increased thyroid-binding globulin. Also,
all subjects in group IV, except one, had normal serum T^. The
exception was a patient with the highest TSH-IRMA (34.3 mU/
L) in whom the serum T^ was 1.1 p.g/dL. Fig 2 shows the distribution of T4 concentrations for subjects in each group. For T^
the mean ± SD for groups I, II, HI, and IV were 10,69 + 3.1,8,79
± 2.61, 8.56 ± 1.42, and 6.95 ± 2.04 pg/dL. respectively. As expected, RU varies widely and did not discriminate between
groups (Fig 2). The RU test reflects thyroxine binding capacity
which is dependent on many other factors in addition to thyroid
status.
As was the case with T^, we were not able to differentiate between the four groups based on FTI because results fell within
our reference range except for a few cases with severe hypothyroidism or hyperthyroidism (Table 2). For this evaluation ofthe
FTI of different groups, we used a reference range which was
previously established on 250 healthy volunteers during employment health examinations (4.5 to 11,0 )ig/dL). When we
used data from the 30 patients tested from group 111 with normal
TSH-IRMA values as a reference range (5,4 to 10.1 pg/dL),
more patients were categorized in the group consistent with the
TSH value. In hypothyroid patients, FTI calculation frequently
adjusted serum T^ values within the normal range to slightly
lower than normal values. In hyperthyroid patients, FTI failed
to adjust serum T^ to higher values in most of the patients (Fig
3). This finding is consistent with the fact that many patients in
this group were receiving thyroxine or had nonthyroidal causes
for the lowered TSH,
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Fig 2—DLstributitm ofT^ (left) and RU (right) in four different
groups. Groups are the same as in Fig 1. Circles represent
group I. triangles group 11. squares group III. and diamonds
group IV. Shaded areas represent the reference range. Horizontal lines represent the means.

Discussion
This study shows that, consistent with other reports (6,7), the
majority of patients tested for thvroid dysfunction had normal
TSH-IRMA (69.9%). The majority of patients fell in group III,
and all of those tested had normal FTI. Thus, our data support
the conclusions of others that normal TSH virtually defines normal thyroid function and that there is no need to measure T4 and
RU or to calculate FTI when TSH-IRMA is within the normal
range (6,7). Most of the subjects with low TSH-IRMA (O.I to
0.4 mU/L) were either euthyroid taking thyroxine supplements
or were normally euthyroid. As expected, TSH was elevated (>
5.0 mU/L) in all the newly diagnosed hypothyroid patients and
suppressed (< 0,1 mU/L) in all but one of the hyperthyroid pafients which was enough to make the correct diagnosis. T4, RU,
and FTI did not indicate the correct thyroid status of those patients. Surprisingly, 50% of group I and 93.3% of group IV had
normal T4. FTI was even less helpful in predicting the correct
diagnosis of hypothyroidism and hyperthyroidism, being normal in 93.3% and 80%, respecfively. Most group II patients,
with low TSH-IRMA, had normal T4, RU. and FTI. We are not
confident that measurement of T4 and RU and calculating FTI
adds much understanding of the thyroid status of these patients
(8). Our study shows that all but one were euthyroid clinically
and most had normal T4 and FTI. However, examining T4, RU,
and FTI confirmed euthyroidism and helped in understanding
the thyroid status when other factors affected the thyroid function tests. Determining T4. RU. and FTI would help uncover developing hyperthyroidism as well as pituitary or hypothalamic
hypothyroidism. Although TSH-IRMA alone is sufficient to
make the correct diagnosis in new cases of hypothyroidism and
hyperthyroidism, results of T4 and RU confirm the initial diagnosis and establish baseline values before starting therapy (6,7).
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Fig 3—Relationship between total thyroxine (TJ and free thyroxine index (FTI) in hyperthyroid patients (left) and hypothyroid patients (right).

To measure T4, much less RU, in addition to TSH-IRMA is
probably not important when monitoring thyroxine therapy or
following established thyroid disease. In contrast, T4 and/or RU
should be used in following patients with pituitary and hypothalamic hypothyroidism for which TSH-IRMA measurement is of
limited diagnostic value.
The failure of FTI and T4 to idenfify pafients with hyperthyroidism probably reflects the mild nature of the newly diagnosed disorder. About half of these patients were hyperthyroid
secondary to over-replacement with thyroxine. TSH is a more
sensitive diagnostic test because the pituitary thyrotroph senses
early elevation in serum thyroxine which results in suppression
of TSH before other clinical and biochemical indices are affected. In severe cases of hyperthyroidism where serum T4 is elevated, the binding proteins became more saturated so that the
FTI exceeds the serum T4 value. Selecting a more narrow reference range for FTI improves diagnostic usefulness (Fig 4),
A testing strategy for the evaluation of thyroid function and
the use of computer technology based on TSH-IRMA results
has a number of advantages: 1) the number of tests required to
reach a diagnosis is minimized, diagnostic efficiency is enhanced, and costs reduced; 2) only a single blood specimen is required as the computer program ensures that appropriate orders
forT4 and RU appear on the laboratory worksheet of the original
sample, further limifing cost and inconvenience to the patient;
3) a computer-generated calculafion of FTI (the product of T4
and RU) is readily available as part of the final report; and 4) this
two-step approach (initial TSH-IRMA order and subsequent decision about further tests) offers the clinician a systemafic means
of idenfifying patients who require further evaluation. There are
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Fig 4—Free thyroxine index in the four groups. Horizontal lines
represent the means. Shaded areas represent the reference
range. * = Mean ± 2 SD of 30 normal euthyroid patients. Circles represent group I. triangles group II. squares group III. and
diamonds group IV.

two limitations to the DRTSH algorithm. First, it may provide
misleading data in patients with hypothalamic-pituitary disease.
In these patients it is appropriate to order an FTI directly because
the TSH can be within normal limits. Thyrotropin-releasing
hormone stimulation test of TSH may yield additional information in this group (13). Second, clinical judgment must be used
in the interpretafion of low TSH values (0.1 to 0.5 mU/L), particularly in hospitalized patients with other illnesses.

Conclusion
The thyroid tesfing algorithm DRTSH effectively distinguishes euthyroid individuals from hypothyroid and hyperthyroid subjects, and measurement of T4, RU, and FTI is not required unless central hypothyroidism or hyperthyroidism is suspected. Because results in a large proportion of evaluated individuals fall within the normal range, the number of tests is reduced. For patients with serum TSH-IRMA values < 0.1 mU/L
or > 5.0 mU/L, serum T4 and serum RU measured at the initial
evaluation usually confirm the inifial impression. Because most
patients in all groups have a normal FTI, in stable and well-studied subjects, e.g., those receiving long-term thyroxine therapy,
the follow-up tests T4 and RU generated by the algorithm may
not be useful. In these patients TSH-IRMA alone is an adequate
monitor ofthe effectiveness of therapy. For patients not receiving thyroxine but in whom the serum TSH-IRMA value lies between 0.1 to 0.4 mU/L, additional information may be necessary
to understand the thyroid status. Certainly, TSH-IRMA is more
sensifive than FTI in distinguishing between euthyroid and noneuthyroid patients. Although cost data are not reported here.

Thyroid Testing Algorithm—Ibrahim el al

33

DRTSH is both effective and cost-efficient in the evaluation of
thyroid function (11).
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